INARI MEDICAL

COMPANY PROFILE – NOVEMBER 2021

EXTRACTING LARGE CLOTS FROM LARGE VESSELS WITHOUT THE NEED FOR THROMBOLYTICS OR ICU STAY

Inari Medical is committed to treating and transforming the lives of patients suffering from venous diseases through pioneering devices specifically designed and purpose-built for the venous anatomy and its unique clot morphology.

CURRENT MARKETS AND PRODUCTS:

Offering highly differentiated products in the venous space, treating Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)

PULMONARY EMBOLISM (PE) [1]

THE CHALLENGE:

- Blood clots that break loose and travel into the lungs
- 3rd leading cause of cardiovascular death
- #1 cause of preventable deaths in hospitals
- 12-50% short-term mortality across massive and sub-massive PE

THE INARI SOLUTION:

THE FLOWTRIEVER® SYSTEM

PROCEDURE MIX: 49%

- A large bore catheter-based aspiration and mechanical thrombectomy system designed to remove large clots from large venous vessels to treat PE
- In May of 2018, the FlowTriever System received FDA approved labeling, making it the first mechanical thrombectomy device indicated for the treatment of Pulmonary Embolism (PE)
- In January of 2021, FlowTriever received received 510(k) market clearance from the U.S. FDA for Right Atrial Clot In Transit, becoming the first thrombectomy system not requiring a cardiopulmonary bypass circuit for blood clots in the right atrium

DEEP VEIN THROMBOSIS (DVT) [2]

THE CHALLENGE:

- Blood clots that form in the deep venous system
- ~50% of patients are expected to develop post-thrombotic syndrome (PTS), a chronic, lifestyle-limiting disease comprising swelling, pressure, chronic pain and ulcers
- Nearly 90% of PTS patients are unable to work 10 years after diagnosis

THE INARI SOLUTION:

THE CLOTTRIEVER® SYSTEM

PROCEDURE MIX: 51%

- Designed to core, capture and remove large clots from large venous vessels
- In February of 2017, the ClotTriever System received 510(k) marketing clearance from the U.S. FDA for the non-surgical removal of thrombi and emboli from the peripheral vasculature

FINANCIAL PROFILE

Robust quarterly revenue growth with gross margins of >80%



1. "Pulmonary Embolism in 2017: Increasing Options for Increasing Incidence", National Center for Biotechnology Information, May2017.
2. Kahn SR, Arch Intern Med 2004

FAST FACTS

PATIENT FOCUSED
Pursuing extraordinary outcomes and improving the quality of life for patients since 2018

>37,000 patients treated to date

PRODUCT SIMPLICITY
Intuitive, easy to use, single-use devices that do not require capital equipment or the use of thrombolytic drugs

COMPELLING PROCEDURE ECONOMICS
Products allow for short, single sessions and are designed to eliminate need for expensive thrombolytics which require costly ICU stays and carry risks of major bleeding

COMMITTMENT TO CLINICAL DATA
Significant clinical research investment. Real world and broad evidence generation to drive adoption. Studies and registries include: FLARE, CLOUT, FLASH, and FLAME

SCALING COMMERCIAL ORGANIZATION
Rapidly growing US commercial organization designed to harness and leverage unique insights into key business decisions. Commencing international expansion in Europe and Asia

MARKET OPPORTUNITY
Combined addressable market of $3.8B in the US. Significant international market opportunity as well

MARQUEE MED TECH IPO
1st non-biotech IPO post COVID-19 outbreak, completed May, 2020

(NASDAQ: NARI)

CONTACT INFORMATION

6001 Oak Canyon, Ste #100 Irvine, CA 92618, U.S

Steinenbachgaesslein 49, 4051 Basel, Switzerland

info@inarimedical.com

www.inarimedical.com